Geode Capital Management
CTXR icon

Geode Capital Management’s Citius Pharmaceuticals CTXR Stock Holding History

Geode Capital Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$222K Buy
246,158
+118,625
+93% +$95.8K ﹤0.01% 3874
2025
Q4 		$99.1K Buy
127,533
+7,762
+6% +$9.71K ﹤0.01% 4100
2025
Q3 		$149K Buy
119,771
+43,676
+57% +$60.9K ﹤0.01% 4020
2025
Q2 		$121K Sell
76,095
-13,180
-15% -$12.1K ﹤0.01% 4014
2025
Q1 		$133K Buy
89,275
+12,769
+17% +$30.6K ﹤0.01% 3950
2024
Q4 		$306K Buy
76,506
+1,348
+2% +$9.08K ﹤0.01% 3754
2024
Q3 		$941K Buy
75,158
+9,306
+14% +$157K ﹤0.01% 3373
2024
Q2 		$961K Sell
65,852
-51,968
-44% -$931K ﹤0.01% 3321
2024
Q1 		$2.64M Buy
117,820
+6,624
+6% +$121K ﹤0.01% 3010
2023
Q4 		$2.1M Buy
111,196
+4,181
+4% +$79.3K ﹤0.01% 3085
2023
Q3 		$1.83M Buy
107,015
+2,694
+3% +$64K ﹤0.01% 3099
2023
Q2 		$3.13M Buy
104,321
+50,770
+95% +$1.67M ﹤0.01% 2947
2023
Q1 		$1.57M Buy
53,551
+246
+0.5% +$7.09K ﹤0.01% 3133
2022
Q4 		$1.05M Buy
53,305
+373
+0.7% +$10.2K ﹤0.01% 3316
2022
Q3 		$1.6M Buy
52,932
+530
+1% +$14.6K ﹤0.01% 3163
2022
Q2 		$1.21M Sell
52,402
-38,484
-42% -$1.06M ﹤0.01% 3340
2022
Q1 		$4.07M Buy
90,886
+8,917
+11% +$352K ﹤0.01% 2918
2021
Q4 		$3.15M Sell
81,969
-3,276
-4% -$149K ﹤0.01% 3143
2021
Q3 		$4.33M Buy
85,245
+9,025
+12% +$453K ﹤0.01% 2995
2021
Q2 		$6.63M Buy
76,220
+42,052
+123% +$2.53M ﹤0.01% 2739
2021
Q1 		$1.52M Buy
34,168
+28,370
+489% +$1.13M ﹤0.01% 3387
2020
Q4 		$147K Hold
5,798
– – ﹤0.01% 3975
2020
Q3 		$150K Buy
5,798
+3,028
+109% +$85.6K ﹤0.01% 3803
2020
Q2 		$78K Buy
+2,770
New +$60.6K ﹤0.01% 3912

Other funds holding CTXR

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management's CTXR Position: Q1 2026 in Review

Geode Capital Management increased its Citius Pharmaceuticals (CTXR) stake by 93% in Q1 2026, buying an estimated $95.8K and bringing the position to 246,158 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #3874.

Geode Capital Management first reported a position in CTXR in Q2 2020 and has held it in 24 quarters since. The position peaked at $6.63M in Q2 2021. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • Geode Capital Management held 246,158 shares of Citius Pharmaceuticals worth $222K as of Q1 2026.
  • Geode Capital Management bought 118,625 Citius Pharmaceuticals shares in Q1 2026, an estimated $95.8K.
  • Citius Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3874 holding.
  • Geode Capital Management first reported a position in Citius Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Geode Capital Management's Citius Pharmaceuticals position peaked at $6.63M in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.